<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id>
<journal-id journal-id-type="hwp">jco</journal-id>
<journal-id journal-id-type="pmc">jco</journal-id>
<journal-id journal-id-type="publisher-id">JCO</journal-id>
<journal-title-group>
<journal-title>Journal of Clinical Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0732-183X</issn>
<issn pub-type="epub">1527-7755</issn>
<publisher>
<publisher-name>American Society of Clinical Oncology</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28640700</article-id>
<article-id pub-id-type="pmc">5516481</article-id>
<article-id pub-id-type="publisher-id">717199</article-id>
<article-id pub-id-type="doi">10.1200/JCO.2016.71.7199</article-id>
<article-categories>
<subj-group subj-group-type="subject">
<subject>Brain Tumors</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Special Series Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>CNS Tumors in Neurofibromatosis</article-title>
<alt-title alt-title-type="short">Neurofibromatosis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Campian</surname>
<given-names>Jian</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gutmann</surname>
<given-names>David H.</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
<xref ref-type="corresp" rid="cor1"></xref>
</contrib>
<aff id="aff1">All authors: Washington University School of Medicine, St. Louis, MO.</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Corresponding author: David H. Gutmann, MD, PhD, Department of Neurology, Washington University School of Medicine, Box 8111, 660 South Euclid Ave, St. Louis, MO; e-mail: <email>gutmannd@wustl.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>20</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>22</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>20</day>
<month>7</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>35</volume>
<issue>21</issue>
<fpage>2378</fpage>
<lpage>2385</lpage>
<permissions>
<copyright-statement>Â© 2017 by American Society of Clinical Oncology</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American Society of Clinical Oncology</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="JCO.2016.71.7199.pdf" xlink:title="pdf"></self-uri>
<abstract>
<p>Neurofibromatosis (NF) encompasses a group of distinct genetic disorders in which affected children and adults are prone to the development of benign and malignant tumors of the nervous system. The purpose of this review is to discuss the spectrum of CNS tumors arising in individuals with NF type 1 (NF1) and NF type 2 (NF2), their pathogenic etiologies, and the rational treatment options for people with these neoplasms. This article is a review of preclinical and clinical data focused on the treatment of the most common CNS tumors encountered in children and adults with NF1 and NF2. Although children with NF1 are at risk for developing low-grade gliomas of the optic pathway and brainstem, individuals with NF2 typically manifest low-grade tumors affecting the cranial nerves (vestibular schwannomas), meninges (meningiomas), and spinal cord (ependymomas). With the identification of the <italic>NF1</italic> and <italic>NF2</italic> genes, molecularly targeted therapies are beginning to emerge, as a result of a deeper understanding of the mechanisms underlying <italic>NF1</italic> and <italic>NF2</italic> protein function. As we enter into an era of precision oncology, a more comprehensive awareness of the factors that increase the risk of developing CNS cancers in affected individuals, coupled with a greater appreciation of the cellular and molecular determinants that maintain tumor growth, will undoubtedly yield more effective therapies for these cancer predisposition syndromes.</p>
</abstract>
<counts>
<fig-count count="3"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="89"></ref-count>
<page-count count="9"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name> SJS Export </meta-name>
<meta-value>v1</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>